Revvity speeds up third-quarter growth to 7% and raises its 2026 outlook
Revvity's pro forma organic growth reached 7% in the third quarter, and the company lifted its full-year 2026 growth and margin guidance.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Revvity posted 7% pro forma organic growth in the third quarter. Strength in Life Sciences, a pickup in demand from pharma and biotech customers, and early signs of AI-driven demand spreading across its product lines all contributed.
The company raised its growth and margin guidance for fiscal 2026. It now expects adjusted earnings per share of $5.40 to $5.45.
why it matters
The faster growth and higher outlook suggest demand for lab instruments and reagents is recovering, which could support interest in the stock and in the life sciences tools sector.
market impact
Revvity shares and life sciences tools: demand recovery supports expectations
- Revvity shares pressure up — faster organic growth and a higher 2026 outlook
tags
instruments
sources
- RVTY: Q3 growth accelerated to 7%, lifting FY26 guidance as AI and market recovery broaden demand — TradingView, 3 November 2026 at 14:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗